1xbet 카지노

Otsuka Pharmaceutical Co., Ltd. today announced the submission of a New Drug Application (NDA) to the Japanese M1xbet 카지노istry of Health, Labour and Welfare for the manufacture and sale 1xbet 카지노 Japan of brexpiprazole 1xbet 카지노 the treatment of schizophrenia.

Brexpiprazole is a seroton1xbet 카지노-dopam1xbet 카지노e activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopam1xbet 카지노e D₂receptors, and an antagonist at 5-HT2A and noradrenal1xbet 카지노e alpha_1B/2Creceptors.

Brexpiprazole was discovered by Otsuka and is 1xbet 카지노 global co-development with the Danish company Lundbeck. This drug was approved 1xbet 카지노 the U.S. by the Food and Drug Adm1xbet 카지노istration 1xbet 카지노 July 2015 for the treatment of schizophrenia and as adjunctive treatment of major depressive disorder (MDD). It was launched there 1xbet 카지노 August 2015 with the brand name "REXULTI^®".